According to Mesoblast 's latest financial reports the company's current revenue (TTM) is $7.5 M. In 2022 the company made a revenue of $7.65 M a decrease over the years 2021 revenue that were of $9.88 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $7.5 M | -2.05% |
2022 | $7.65 M | -22.53% |
2021 | $9.88 M | -39.41% |
2020 | $16.31 M | -22.8% |
2019 | $21.13 M | 33% |
2018 | $15.88 M | -0.43% |
2017 | $15.95 M | -49.9% |
2016 | $31.84 M | 33.08% |
2015 | $23.93 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | 1,865.34% | ๐บ๐ธ USA |